March 4, 2013 - Atlanta, GA. The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women’s health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection. Continue Reading...
Do you get our newsletter?
Sign up for our monthly Newsletter and get the latest info in you in box.
Learn what pre-exposure prophylaxis (PrEP) is, how it works, what the research says, new guidelines for using Truvada as PrEP, and more.
The Well Project interviews Maria Mejia: International HIV Activist, Community Advisory Board member and A Girl Like Me blogger.